Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option in the treatment of drug-naïve Korean type 2 diabetic patients. Newly developed thiazolidinedione, Lobeglitazone would be not inferior to Pioglitazone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: 2,4-thiazolidinedione; Metformin; Pioglitazone; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• HbA1c > 13.0 %

• No treatment with insulin or oral agents for 6 months

• 20 ≤ Age < 80 years

Exclusion Criteria:

• Contraindication to sitagliptin or metformin or thiazolidinedione

• Pregnant or breast feeding women

• Type 1 diabetes, gestational diabetes, or secondary forms of diabetes

• Not appropriate for oral antidiabetic agent

• Medication which affect glycemic control

• Disease which affect efficacy and safety of drugs

• Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)